This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study
Sakurai, Hirofumi,
Hanyu, Haruo,
Sato, Tomohiko,
Kume, Kazumasa,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Iwamoto, Toshihiko
Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Cognitive change in donepezil treated patients with vascular or mixed dementia
Rockwood, Kenneth,
Mitnitski, Arnold,
Black, Sandra E.,
Richard, Matthew,
Defoy, Isabelle,
Vaspect study investigators
Background: vascular dementia (VaD) and mixed Alzheimer’s disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE) and other measures potentially usable in primary care.; Methods: A six-month, outcome measurement study. […]
Galantamine treatment in outpatients with mild Alzheimer’s disease
Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson, Anton P.,
Drye, Lea T.,
Pollock, Bruce G.,
Devanand, D. P.,
Frangakis, Constantine,
Ismail, Zahinoor,
Marano, Christopher,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Pelton, Gregory,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Shade, David M.,
Weintraub, Daniel,
Yesavage, Jerome,
Lyketsos, Constantine G.
Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]
Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET
Peters, Ruth,
Beckett, Nigel,
Fagard, Robert,
Thijs, Lutgarde,
Wang, Ji-Guang,
Forette, Francoise,
Pereira, Lisa,
Fletcher, Astrid,
Bulpitt, Christopher
Objectives: High blood pressure (BP) has been associated with increased risk of dementia. Concerns have been raised about lowering BP too far in the very elderly and thereby increasing risk. There is some evidence to suggest a potential ‘J’-shaped relationship between DBP and risk of cognitive impairment. This was investigated using data from the HYpertension […]
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
O'Callaghan, Nathan,
Parletta, Natalie,
Milte, Catherine M.,
Benassi-Evans, Bianca,
Fenech, Michael,
Howe, Peter R.C.
Objectives: Excessive shortening of the telomeric ends of chromosomes is a marker of accelerated aging. Oxidative stress and nutritional deficiency may influence this process. The aim of this study was to investigate the effect of ω-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation on telomeric shortening in elderly individuals with mild cognitive impairment (MCI).; Methods: Thirty-three […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]